Home |Register |Login |Company Information
Our Company
Order Publications
Advertisers
Customer Service
|Survey |Help
Search MPR Database:

The most widely used drug reference by clinicians
Therapeutic Categories Brand Generic Manufacturer News
Drug News
New Products
Resources
Alerts (Sponsored)
Clinical Charts
Prescribing Notes
Manufacturer Index
empr Download We've Got Answers

New Product Releases

November 26, 2008
  • Xenazine
November 6, 2008
  • Sancuso
October 30, 2008
  • Tetrix
October 16, 2008
  • » Akten
October 10, 2008
  • Nplate
October 2, 2008
  • TussiCaps 10mg/8mg
September 19, 2008
  • Cleviprex
September 12, 2008
  • Xyntha
August 29, 2008
  • Stavzor
August 22, 2008
  • Alvesco
August 15, 2008
  • Rotarix
August 7, 2008
  • Tersi Foam
August 1, 2008
  • Fusilev
July 25, 2008
  • Zingo
July 18, 2008
  • Kinrix
July 11, 2008
  • Pentacel
July 3, 2008
  • Lexiscan
June 27, 2008
  • Entereg
June 20, 2008
  • Relistor
June 12, 2008
  • Ferralet 90
June 6, 2008
  • Cimzia
May 30, 2008
  • Treximet
May 22, 2008
  • Patanase
May 16, 2008
  • Treanda
May 9, 2008
  • Omnaris
May 2, 2008
  • Pristiq
April 25, 2008
  • Evamist
April 17, 2008
  • Arcalyst
April 11, 2008
  • Totect
April 4, 2008
  • Simcor 500/20
March 27, 2008
  • Triesence
March 21, 2008
  • Renvela
March 14, 2008
  • Ibudone 5/200
March 7, 2008
  • Intelence
February 29, 2008
  • Tekturna HCT 150/12.5
February 21, 2008
  • Flector Patch
February 14, 2008
  • Fosteum
February 7, 2008
  • Recothrom
January 31, 2008
  • Voltaren Gel
January 25, 2008
  • Veregen
January 17, 2008
  • Bystolic
January 10, 2008
  • Kuvan
January 4, 2008
  • Calomist
Archived Products »

AKTEN Rx

Company:

Akorn

Pharmacologic class:

Local anesthetic

Active ingredient:

Lidocaine HCl 3.5% (35mg/mL); ophthalmic gel; preservative-free.

Indication:

Ocular surface anesthesia during ophthalmologic procedures.

Pharmacology:

Akten is a local anesthetic agent that stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Anesthesia generally occurs between 20 seconds to 1 minute and lasts for 5 to 30 minutes.

Clinical trials:

A total of 209 patients in a double-blind study were randomized to receive either Akten 1.5%, Akten 2.5%, Akten 3.5%, or sham. In this trial, 92% of the Akten 3.5% group achieved ocular anesthesia within 5 minutes of application. The mean time to anesthesia onset was 60 seconds. The duration of anesthesia ranged from 5 to 30 minutes with a mean time of 15 minutes for the Akten 3.5% group. The anesthetic effect of additional applications of Akten has not been evaluated.

Adults and Children:

For single patient use. 2 drops to the ocular surface in area of planned procedure; may reapply as needed.

Precautions:

Not for injection. Prolonged use may cause corneal opacification. Pregnancy (Cat. B).

Adverse reactions:

Conjunctival hyperemia, corneal epithelial changes, headache, burning upon instillation.

How supplied:

Gel—5mL

Last Updated:

10/16/08

From Haymarket Media, Inc. the Publishers of:
Monthly Prescribing Reference Nurse Practitioners' Prescribing Reference Physician Assistants' Prescribing Reference
Cortlandt Forum McKnight's Long-Term Care News Renal & Urology News The Clinical Advisor JAAPA McKnight's Assisted Living
HonCode
© Copyright 2009 | All Rights Reserved. | Disclaimer | Privacy Policy | Site Map | Print Subscription Questions | Online Acct. Help | Subscribe

Online CME
Haymarket Publishing